identify ischaemic and non-ischaemic muscle. The approach utilizes a cyclical variation in the integrated backscatter which occurs in normal myocardium and disappears with ischaemia' 3 " 51 . The paper by Lieback et a/.
[61 in this issue is another effort to use grey scale analysis of the echocardiogram to diagnose myocarditis via tissue. Utilizing digital recordings of the echograms and a fairly sophisticated approach for analysing the grey levels of the various pixels, the authors were able to devise a scheme that identified patients with myocarditis. The scheme permitted them to distinguish myocarditis from healthy myocardium with a very good sensitivity. The basis for their findings was that myocarditis and fibrosis produced changes in echocardiographic brightness, heterogeneity and contrast.
This study is interesting from several points of view. First of all, the investigators used a video display of a standard echocardiographic instrument rather than the radiofrequency display, which is usually not available on commercial instruments. Digital recording is becoming routine on many instruments so that this approach could theoretically be duplicated by others. The algorithms which analyse the grey scale could also be made available. Thus, hopefully, this technique should be able to be confirmed by others without the necessity of expensive complicated instrumentation.
Whether this technique will have wider application besides just the diagnosis of myocarditis is obviously unknown. There are undoubtedly technical limitations to this approach which will limit its usefulness. Many of the patients studied were relatively young and probably had high quality echocardiograms. It is very possible that this approach would not be effective in individuals with less than ideal echocardiograms.
Whether or not this particular approach will have any major clinical value is yet to be determined. However, with the advent of improved ultrasonic imaging and with the increasing use of digital recordings one can anticipate advances in the making of tissue diagnoses using echocardiography. Thus tissue diagnosis will hopefully be added to the list of clinical applications for cardiac ultrasound. . This study, however, provides information of considerable interest because the selection of hypertensive patients was rigorous and the data were properly compared with those obtained for a control group with normal blood pressure. This information supports the conclusion of previous reports that 'echocardiographic' left ventricular hypertrophy is much more frequent than 'ECG' left ventricular hypertrophy. It also confirms that left ventricular hypertrophy increases with age and that its overall prevalence is greater in hypertensive than in normotensive individuals.
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Two other results, however, are different from those of previous epidemiological studies and their implications are of obvious clinical interest. The first result is that in the study of Tingleff et a/. [5] (1) the prevalence of left ventricular hypertrophy was moderately greater in the hypertensive than in the normotensive group as a whole and (2) while left ventricular hypertrophy was definitively more frequent in aged hypertensive patients than in agematched normotensive subjects, in younger hypertensive and normotensive groups left ventricular hypertrophy prevalence showed only a slight and non-significant difference. This may imply that it takes a long time for blood pressure elevation to substantially increase left ventricular mass. It further suggests, however, that the inclusion of echocardiography among the routine investigations performed in hypertensive patients' 6 ' 71 may be of limited usefulness. According to the data of Tingleff et a/.' 51 extensive use of echocardiography should be avoided, particularly in younger hypertensive patients because an increase in left ventricular mass, specifically due to blood pressure elevation, can only rarely be identified in this population of hypertensive subjects, making the cost/ benefit ratio of this examination unfavourable.
The second clinically interesting result provided by Tingleff et a/.' 51 is that in treated hypertensive patients left ventricular hypertrophy prevalence was no less than in untreated hypertensive patients. The authors suggest that this may be due to the wide use of diuretics and beta-blockers (i.e. of drugs with limited ability to reverse left ventricular hypertrophy' 4 ') as antihypertensive drugs of first choice in the population from which those subjects were selected. Their observation of a relatively high prevalence of left ventricular hypertrophy in normotensive subjects, however, suggests that another reason could be the limited specificity of a left ventricular mass increase as a marker of a structural cardiovascular adaptation to hypertension. Finally, because epidemiological studies agree that only a minimal fraction of the hypertensive population is effectively treated' 81 left ventricular hypertrophy persistence in the treated hypertensives of the Tingleff study 151 may just remind us of the unfortunate reality that in general patients' compliance with antihypertensive treatment and blood pressure control are poor.
Studies on the prevalence of left ventricular hypertrophy in different populations should continue because differences might also be due to genetic traits favouring (or opposing) the expression of cardiac muscle or connective tissue hypertrophy. These studies should provide actual left ventricular mass values because in the population left ventricular mass is normally distributed (Pamela study, unpublished observations). Furthermore, in several cases hypertension may push left ventricular mass to greater values without reaching the cut-offs that arbitrary define left ventricular hypertrophy'
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. They should also continue because properly conducted follow-up of these crosssectional surveys will offer the chance to achieve two most important goals. They should aim to show whether not only marked left ventricular hypertrophy but also a modest increase in left ventricular mass carries an increased risk, and whether regression of left ventricular hypertrophy to normal, or only slightly increased left ventricular mass values as a result of antihypertensive treatment favourably affects patients' cardiovascular morbidity and prognosis.
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